MedTrace Logo

Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

NCT02201550 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2014-07-28

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes.

The hypotheses are:

* Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood
* Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood
* Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Conditions

Sponsors & Collaborators

  • Zealand Pharma

    collaborator INDUSTRY

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Carsten Dirksen, MD, PhD · Hvidovre University Hospital

  • Sten Madsbad, MD, DMSc · Hvidovre University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02201550 on ClinicalTrials.gov